At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

The FDA has granted approval for Cosette’s Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

Caused by its namesake virus, chikungunya is a mosquito-borne disease mainly found in tropical regions, although coverage is spreading. Credit: Loomo Digital/Shutterstock.com. The UK’s Medicines and ...

Sanofi has signed a global licensing and strategic collaboration agreement with ScionxBio to develop long-acting mRNA therapies using the TERA platform.

The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.

The planned takeover of Silence is the third major acquisition for Merck in less than two years. Credit: Kittyfly/Shutterstock.com. Merck KGaA has agreed to buy short interfering RNA (siRNA) drug ...

Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.

UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare products Regulatory Agency (MHRA) said it would consider allowing ...